Palisade Bio wins FDA IND clearance for PALI-2108 Crohn’s disease Phase 2 trial
Bitget2026/09/22 12:35- Palisade Bio received FDA clearance of its IND for PALI-2108, enabling a Phase 2 trial in moderate to severe Crohn’s disease.
- ASCENTRA-CD is set to enroll about 60 patients; first dosing targeted for Q1 2027.
- Primary efficacy readout targeted for Q1 2028, based on Week 12 endoscopic response.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Crypto prices
More
